BAM
ATRC icon

Blueshift Asset Management’s AtriCure ATRC Stock Holding History

Blueshift Asset Management’s Portfolio ATRC Stock Details ATRC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-9,708
Closed -$675K – 844
2021
Q3 		$675K Buy
+9,708
New +$747K 0.04% 528

Other funds holding ATRC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Blueshift Asset Management's ATRC Position: Q4 2021 in Review

Blueshift Asset Management sold out of AtriCure (ATRC) in Q4 2021, closing a stake of 9,708 shares — an estimated $675K sold.

Blueshift Asset Management first reported a position in ATRC in Q3 2021 and held it in 1 quarter. The position peaked at $675K in Q3 2021. 217 funds tracked by Wall St. Rank hold ATRC as of Q4 2021.

  • Blueshift Asset Management reported no remaining AtriCure position as of Q4 2021 after selling out during the quarter.
  • Blueshift Asset Management sold 9,708 AtriCure shares in Q4 2021, an estimated $675K.
  • Blueshift Asset Management first reported a position in AtriCure in Q3 2021 and held it in 1 quarter.
  • Blueshift Asset Management's AtriCure position peaked at $675K in Q3 2021.
  • 217 funds tracked by Wall St. Rank held AtriCure as of Q4 2021.

Based on Blueshift Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.